| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2011: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Research Abstract |
Ghrelin is reported to have anti-inflammatory effects by inhibiting the expression of inflammatory cytokines. We performed randomized, placebo-controlled phase II study to investigate the clinical efficacy and feasibility of administering ghrelin in the patients undergoing esophagectomy. A total of 40 patients with primary esophageal cancer were assigned into either a ghrelin (n=20) or placebo (n=20) group. There were no significant differences in the background characteristics in both groups. Patients treated with ghrelin showed shorter SIRS durations than controls and they showed lower C-reactive protein and interleukin-6 concentrations than controls. Ghrelin administration was not associated with any adverse events. In conclusion, the present study showed that ghrelin administration in the early postoperative phase was safe and able to improve inflammation after esophagectomy.
|
